TY - JOUR
T1 - Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians
AU - Rasmussen, Søren K.
AU - Urhammer, Søren A.
AU - Berglund, Lars
AU - Jensen, Jan N.
AU - Hansen, Lars
AU - Echwald, Søren M.
AU - Borch-Johnsen, Knut
AU - Horikawa, Yukio
AU - Mashima, Hirosato
AU - Lithell, Hans
AU - Cox, Nancy J.
AU - Hansen, Torben
AU - Bell, Graeme I.
AU - Pedersen, Oluf
PY - 2002/12/1
Y1 - 2002/12/1
N2 - Variations in the calpain-10 gene (CAPNIO) have been identified among Mexican-Americans, and an at-risk haplotype combination (112/121) defined by three polymorphisms, UCSNP-43, -19, and -63, confers increased risk of type 2 diabetes. Here we examine the three polymorphisms in 1,594 Scandinavian subjects, including 409 type 2 diabetic patients, 200 glucose-tolerant control subjects, 322 young healthy subjects, 206 glucose-tolerant offspring of diabetic patients, and 457 glucose-tolerant 70-year-old men. The frequency of the 112/121 combination was not significantly different in 409 type 2 diabetic subjects compared with 200 glucose-tolerant control subjects (0.06 vs. 0.05; odds ratio 1.32 [95% CI 0.58-3.30]). In glucose-tolerant subjects, neither the single-nucleotide polymorphisms individually nor the 112/121 combination were associated with alterations in plasma glucose, serum insulin, or serum C-peptide levels at fasting or during an oral glucose tolerance test, estimates of insulin sensitivity, or glucose-induced insulin secretion. In conclusion, the frequency of the 112/121 at-risk haplotype of CAPN10 is low among Scandinavians and we were unable to demonstrate significant associations between the CAPNIO variants and type 2 diabetes, insulin resistance, or impaired insulin secretion.
AB - Variations in the calpain-10 gene (CAPNIO) have been identified among Mexican-Americans, and an at-risk haplotype combination (112/121) defined by three polymorphisms, UCSNP-43, -19, and -63, confers increased risk of type 2 diabetes. Here we examine the three polymorphisms in 1,594 Scandinavian subjects, including 409 type 2 diabetic patients, 200 glucose-tolerant control subjects, 322 young healthy subjects, 206 glucose-tolerant offspring of diabetic patients, and 457 glucose-tolerant 70-year-old men. The frequency of the 112/121 combination was not significantly different in 409 type 2 diabetic subjects compared with 200 glucose-tolerant control subjects (0.06 vs. 0.05; odds ratio 1.32 [95% CI 0.58-3.30]). In glucose-tolerant subjects, neither the single-nucleotide polymorphisms individually nor the 112/121 combination were associated with alterations in plasma glucose, serum insulin, or serum C-peptide levels at fasting or during an oral glucose tolerance test, estimates of insulin sensitivity, or glucose-induced insulin secretion. In conclusion, the frequency of the 112/121 at-risk haplotype of CAPN10 is low among Scandinavians and we were unable to demonstrate significant associations between the CAPNIO variants and type 2 diabetes, insulin resistance, or impaired insulin secretion.
UR - http://www.scopus.com/inward/record.url?scp=0036895104&partnerID=8YFLogxK
U2 - 10.2337/diabetes.51.12.3561
DO - 10.2337/diabetes.51.12.3561
M3 - Article
C2 - 12453914
AN - SCOPUS:0036895104
SN - 0012-1797
VL - 51
SP - 3561
EP - 3567
JO - Diabetes
JF - Diabetes
IS - 12
ER -